Real-World Effectiveness of Risankizumab in Patients With Psoriatic Arthritis: 6-Month Interim Results From the Observational PErsistence With RISankizumab (PERIS) Study (ACR Convergence 2026) - Sep 8, 2026 - Abstract #1326; Pres time: Nov 9, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; No abstract available
Clinical • Real-world • Real-world effectiveness • Real-world evidence • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies
|